Charles River Laboratories snaps up Cognate for a cool $875M, looks to expand cell and gene therapy CDMO foothold
With the cell and gene therapy space as hot as ever, big-name CDMO Charles River Laboratories is looking to carve out a big piece of the pie. To get there, it’s snapping up a Memphis-based specialist in the space.
Charles River Laboratories announced Wednesday that it acquired Cognate BioServices, a cell and gene therapy specialist with operations in the US and EU.
The move will build Charles River’s foothold in the cell and gene industry as it absorbs Cognate’s tech, which is also used in cellular immunotherapy and immuno-oncology, regenerative medicine, and advanced cell therapy therapeutics. Not to mention the company’s 500+ employees, which will join some 17,000+ Charles River workers.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,900+ biopharma pros reading Endpoints daily — and it's free.